Tests burning nerve endings in the heart to treat recurrent atrial fibrillation
Tests ablation of heart nerve endings in adults whose atrial fibrillation returned after treatment.
Plain-language title generated from the registry record
Registry title: The Role of Right Atrial Ectopy Triggering Ganglionated Plexuses in AF
Key facts
- Where
- London, United KingdomSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 85 with symptomatic paroxysmal atrial fibrillation who can have catheter ablation.
- Age
- 18 to 85 years
- Sex
- Men and women can join.
- Disease stage
- Symptomatic paroxysmal atrial fibrillation.
Main reasons for not taking part
- Any form of cardiomyopathy
- Moderate or worse valvular disease
- Moderate to severe heart failure (NYHA Class III-IV)
- Uncontrolled diabetes
- Pregnancy, or women who could become pregnant and do not use a highly effective method of contraception
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT05539040, who can take part
Where in United Kingdom
- Hammersmith HospitalLondon, United KingdomTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Imperial College London
- Trial code
- NCT05539040
- Record updated
- 28 September 2023
- Original description
Atrial fibrillation (AF) is the most common rhythm disturbance of the heart. It can affect people of any age but usually happens as we get older. It can cause palpitations, breathlessness, lethargy, and fainting attacks. It is also associated with an increased risk of strokes.Read full original descriptionShow less
Understanding the Role of Right Atrial Ectopy-triggering Ganglionated Plexuses in Atrial Fibrillation
Atrial fibrillation (AF) is the most common rhythm disturbance of the heart. It can affect people of any age but usually happens as we get older. It can cause palpitations, breathlessness, lethargy, and fainting attacks. It is also associated with an increased risk of strokes.
The best treatment for it at the moment involves burning or freezing (ablation) the heart muscle in a part of the heart called the left atrium. The ablation injures the heart muscle around the so-called pulmonary veins and the procedure is called a 'pulmonary vein isolation'. This procedure work in about 60% of people.
The study team have found that there are nerve endings in the heart that also cause AF and have shown that ablating these nerve endings also prevents AF. These Nerve endings are known as ganglionated plexuses (GPs).
The study team would now like to perform a trial in people who still have AF after the usual pulmonary vein procedure. The study team hope that ablating the nerve endings that cause AF (GPs), we will stop their AF coming back. The study team will compare this procedure to the normal approach of doing the pulmonary vein isolation again
Inclusion: Males or females from 18 to 85yrs old; Symptomatic paroxysmal atrial fibrillation; Suitable candidate for catheter ablation; Signed informed consent.
Exclusion: Valvular disease that is grade moderate or greater; Severe cerebrovascular disease; Active gastrointestinal bleeding; Active infection or fever; Allergy to contrast; Moderate to severe heart failure and/or NYHA Class III-IV; Bleeding or clotting disorders or inability to receive heparin; Malignancy needing therapy; Serum Creatinine >200umol/L/ on dialysis/ at risk of dialysis; Uncontrolled diabetes (HbA1c ≥73mmol/mol or HbA1c ≤64mmol/mol and Fasting Blood Glucose ≥9.2mmol/L); Contraindication to catheter ablation; Contraindication for general anaesthetic; Presence of a left ventricular thrombus; Any form of cardiomyopathy; Life expectancy shorter than the duration of the trial; Pregnancy or women of childbearing potential not using a highly effective method of contraception; Unable to give informed consent.